Hajhullás kezelések

Hair loss kezelések Európában

Hair loss — medically referred to as alopecia — affects a significant proportion of the European population. Androgenetic alopecia, commonly known as male or female pattern baldness, is the most prevalent form. It is estimated that approximately 50% of men experience noticeable hair loss by the age of 50, and female pattern hair loss is also more common than widely recognised, affecting an estimated 40% of women by the age of 70.

Androgenetic alopecia is driven primarily by genetic predisposition and the action of dihydrotestosterone (DHT), a potent androgen derived from testosterone via the enzyme 5-alpha reductase. DHT causes miniaturisation of hair follicles, leading to progressively finer and shorter hair until follicles are no longer productive. The pattern of loss differs between males and females: men typically experience recession at the temples and crown, while women more commonly experience diffuse thinning over the top of the scalp.

The psychological impact of hair loss should not be underestimated. Research published in peer-reviewed journals has consistently documented associations between hair loss and reduced self-esteem, anxiety, and in some cases clinical depression. The availability of effective pharmacological treatments has improved significantly over recent decades, offering meaningful benefit for many patients when treatment is initiated early.

Prescription medications for hair loss work through different mechanisms. Finasteride and dutasteride reduce DHT levels systemically. Minoxidil, available in both topical and oral formulations, acts as a vasodilator that prolongs the growth phase of hair follicles. All treatment decisions should be made by a qualified, independent doctor based on thorough clinical assessment.

Elérhető kezelések

The following medications are available for hair loss treatment through EU-registered doctors. This comparison is provided for informational purposes only. A doctor will assess which medication, if any, is appropriate for your individual situation.

Key distinctions:

• Finasteride: The first-line oral treatment for male androgenetic alopecia. Clinical studies show it can halt progression and promote regrowth in the majority of men. Not appropriate for women of childbearing potential.
• Minoxidil: Available in topical and, increasingly, low-dose oral formulations. Approved for use in both men and women. Effective as monotherapy or in combination with finasteride.
• Dutasteride: Achieves higher DHT suppression than finasteride due to dual enzyme inhibition. Some clinical evidence supports greater efficacy, but it carries an off-label status for hair loss in most EU jurisdictions. A doctor will advise whether it is appropriate for you.

Hogyan szerezhető be a kezelések online

A Prescrivia technológiai közvetítőként működik: nem írunk fel gyógyszereket, nem alkalmazunk orvosokat és nem értékesítünk gyógyszereket. Platformunk pácienseket kapcsol össze független, EU-ban regisztrált orvosokkal, akik bizalmas online egészségügyi felméréseket végezhetnek.

A folyamat a következő:

1. Töltse ki az egészségügyi kérdőívet — Answer a structured set of medical questions covering the pattern and duration of your hair loss, family history, current medications, and relevant medical history. Photos may be requested to support the clinical assessment.

2. Independent doctor review — An independent EU-registered doctor reviews your assessment. If a hair loss medication is clinically appropriate, the doctor may issue a prescription. If it is not appropriate for your circumstances, the doctor will explain the reasoning.

3. Recept és teljesítés — If a prescription is issued, it is passed to a licensed EU pharmacy partner. The pharmacy dispenses the medication and arranges delivery directly to your address.

Fontos: A Prescrivia nem garantálja a recept kiállítását. Minden felírási döntést független, képzett orvosok hoznak az Ön egyéni klinikai körülményei alapján. Prescription hair loss medications require a valid prescription from a licensed doctor.

Összehasonlításunk

Note: Sudden or patchy hair loss, hair loss accompanied by scalp changes, or loss that may be secondary to an underlying medical condition (such as thyroid disease or nutritional deficiency) warrants in-person investigation before treatment. Prescrivia’s platform is designed for adults whose hair loss pattern is consistent with androgenetic alopecia suitable for remote assessment.

Források

Az oldalon található orvosi információk az alábbi forrásokon alapulnak:

• European Medicines Agency (EMA). Propecia (finasteride) — Summary of Product Characteristics. Available at: ema.europa.eu
• Blumeyer A, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and men. JDDG. 2011;9(S6).
• World Health Organization (WHO). Dermatological conditions — regional data. who.int

Ez a tartalom rendszeresen felülvizsgálatra kerül a frissített klinikai irányelvek tükrözése érdekében. Kizárólag tájékoztató jelleggel készült, és nem minősül orvosi tanácsadásnak. Mindig konzultáljon képzett egészségügyi szakemberrel az Ön egyéni egészségügyi körülményeire vonatkozó tanácsért.